Business Context and Reporting Period
This Form 8-K is a current report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on June 14, 2022. The filing documents the results of the Company's 2022 Annual Meeting of Stockholders and reports on regulatory correspondence regarding its clinical development program.
Key Financial Metrics
This filing is a current report regarding corporate governance and regulatory events. It does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's Form 10-K or 10-Q for financial data.
Material Changes and Corporate Actions
- Stockholder Approval of Incentive Plan: Stockholders approved the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (OIP). The plan authorizes the issuance of up to 2,400,000 shares of common stock for awards including stock options, restricted stock, and performance awards.
- Director Elections: Five Class II director nominees were elected to the Board of Directors for two-year terms: Sir Marc Feldmann, Ph.D., Larry Gold, Ph.D., Donald A. McGovern, Jr., MBA, Teresa M. DeLuca, M.D., MBA, and Pamela G. Marrone, Ph.D.
- Auditor Ratification: Stockholders ratified the appointment of Marcum LLP as the independent auditor for the fiscal year ending December 31, 2022.
- Regulatory Correspondence: The Company received correspondence from regulatory authorities in the United States and United Kingdom regarding its planned use of adalimumab (anti-TNF treatment) for early-stage Dupuytren's disease.
Voting Results Summary
| Proposal | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (All 5 Nominees) | 8.2M - 8.6M | 62K - 503K | 0 | 10,081,990 |
| Adoption of 2022 Omnibus Incentive Plan | 8,135,159 | 509,917 | 65,808 | 10,082,065 |
| Ratification of Auditors (Marcum LLP) | 18,679,886 | 90,474 | 22,589 | 0 |
Note: Total outstanding voting shares as of the record date were 34,092,519. Approximately 55.1% of shares were present or voted.
Outlook, Risks, and Contingencies
- Regulatory Risk: The filing highlights correspondence from US and UK regulators concerning the Company's clinical strategy for Dupuytren's disease. The specific content of this correspondence is detailed in the press release filed as Exhibit 99.1.
- Forward-Looking Statements: The filing includes standard disclaimers that forward-looking statements regarding future financial performance and clinical results are subject to risks and uncertainties that may cause actual results to differ materially.
Key Facts for Investor Verification
- Verify the specific content of the regulatory correspondence regarding adalimumab and Dupuytren's disease by reviewing Exhibit 99.1 (Press Release) attached to this filing.
- Confirm the dilution impact of the newly approved 2,400,000 share limit under the 2022 Omnibus Incentive Plan.
- Review the Company's most recent Form 10-Q or 10-K for actual financial performance, as this 8-K contains no financial data.
- Note the high number of broker non-votes (approx. 10 million) on director elections, indicating significant shares held in street name where brokers did not have discretionary voting authority.